Medicare Enrolled

Dr. Sanober Kable, MD

Critical Care Medicine · Denison, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
5012 US HWY 75 STE 200, Denison, TX 75020
9034655012
In practice since 2007 (19 years)
NPI: 1295876399 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Kable from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kable? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Kable

Dr. Sanober Kable is a critical care medicine in Denison, TX, with 19 years in practice. Based on federal Medicare data, Dr. Kable performed 40,935 Medicare services across 4,921 unique beneficiaries.

Between the years covered by Open Payments, Dr. Kable received a total of $239,350 from 58 pharmaceutical and/or device companies across 1728 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in critical care medicine. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Kable is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 0% volume in TX$ $239,350 industry payments

Medicare Practice Summary

Medicare Utilization ↗
40,935
Medicare services
Top 0% in TX for critical care medicine
4,921
Unique beneficiaries
$35
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,154 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Omalizumab injection (Xolair) for asthma/allergy17,117$30$40
Injection, mepolizumab, 1 mg14,270$23$60
Injection, benralizumab, 1 mg1,740$132$250
Office visit, established patient (30-39 min)1,327$93$210
Drug injection, under skin or into muscle974$11$79
Allergy skin test937$3$10
Office visit, established patient (20-29 min)690$65$150
Test to examine how well the lungs exchange gases660$41$149
Test to determine lung volumes using sensors631$39$150
Test for exercise-induced lung stress549$24$100
Test to measure expiratory airflow and volume changes before and after medication administration449$28$150
Hospital follow-up visit, moderate complexity284$59$140
Test to measure expiratory airflow and volume221$20$100
New patient office visit (45-59 min)201$123$320
New patient office visit (30-44 min)140$78$210
Injection, methylprednisolone acetate, 20 mg130$4$30
Irrigation and suction of lung airways to obtain cells using an endoscope89$14$600
Sleep study in sleep lab with continuous airway pressure (6 years or older)85$95$889
Biopsy of lobe of lung using an endoscope, 1 lobe82$94$700
Initial hospital admission, moderate complexity68$95$270
Sleep study in sleep lab (6 years or older)64$90$240
Ceftriaxone antibiotic injection42$0$35
Hospital follow-up visit, high complexity35$92$205
Needle biopsy of windpipe cartilage, airway, and/or lung using an endoscope32$125$1,125
Sleep study including heart rate, breathing, airflow, and effort26$66$456
Exam of lung airways using an endoscope25$8$479
Computer-assisted image-guided navigation of lung airways using an endoscope24$73$1,998
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle20$54$200
Insertion of tube in right heart chambers for measurement12$98$1,470
Initial hospital admission, high complexity11$134$400
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$239,350
Total received (2018-2024)
Avg $34,193/year across 7 years
Top 1% in TX for critical care medicine
58
Companies
1,728
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$213,419 (89.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,403 (6.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$9,528 (4.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$52,440
2023
$38,493
2022
$26,478
2021
$32,967
2020
$27,550
2019
$21,755
2018
$39,665

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$81,981
AstraZeneca Pharmaceuticals LP
$55,022
GENZYME CORPORATION
$30,689
Sunovion Pharmaceuticals Inc.
$22,327
JAZZ PHARMACEUTICALS INC.
$10,205
United Therapeutics Corporation
$9,447
Bayer HealthCare Pharmaceuticals Inc.
$9,071
Intuitive Surgical, Inc.
$4,840
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,901
Mylan Specialty L.P.
$1,371
Actelion Pharmaceuticals US, Inc.
$1,364
Boston Scientific Corporation
$1,271
ZOLL Respicardia, Inc.
$1,189
Takeda Pharmaceuticals U.S.A., Inc.
$940
Electromed, Inc.
$912
Regeneron Healthcare Solutions, Inc.
$731
Genentech USA, Inc.
$641
Bayer Healthcare Pharmaceuticals Inc.
$612
Grifols USA, LLC
$568
Novartis Pharmaceuticals Corporation
$411
Insmed, Inc.
$365
Pulmonx Corporation
$329
Ethicon Inc.
$256
Jazz Pharmaceuticals Inc.
$254
Philips Electronics North America Corporation
$240
Mallinckrodt LLC
$227
Amgen Inc.
$214
Baxter Healthcare
$214
Janssen Pharmaceuticals, Inc
$192
Advanced Respiratory, Inc
$173
Veran Medical Technologies, Inc.
$158
Tactile Systems Technology Inc
$145
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$98
Axsome Therapeutics, Inc.
$93
ADVANCED RESPIRATORY, INC
$87
Gilead Sciences, Inc.
$81
Harmony Biosciences LLC
$74
HARMONY BIOSCIENCES LLC
$66
CSL Behring
$64
PFIZER INC.
$61
Eisai Inc.
$47
Mallinckrodt Hospital Products Inc.
$45
Shire North American Group Inc
$43
Mallinckrodt Enterprises LLC
$41
Exeltis, USA Inc.
$39
Circassia Pharmaceuticals Inc
$33
Vapotherm Inc
$32
Merck Sharp & Dohme LLC
$26
Supernus Pharmaceuticals, Inc.
$22
Avadel CNS Pharmaceuticals, LLC
$21
Covis Pharma GmBH
$19
Cumberland Pharmaceuticals, Inc.
$19
Merck Sharp & Dohme Corporation
$16
Inogen, Inc.
$16
E.R. Squibb & Sons, L.L.C.
$14
Pernix Therapeutics Holdings, Inc.
$14
Currax Pharmaceuticals LLC
$11
INOGEN, INC.
$7
Top 3 companies account for 70.1% of total payments
Associated products mentioned in payments ›
(8874) inCourage · ACQUIRE · ACTHAR · AIRSUPRA · ANORO · ANORO ELLIPTA · APTIOM · AREXVY · Adempas · Arikayce · BEVESPI AEROSPHERE · BREO · BREO ELLIPTA · BREZTRI · BREZTRI AEROSPHERE · BROVANA · Belviq · CHANTIX · CHARTIS CATHETER · CONTRAVE · CUVITRU · DUPIXENT · Da Vinci Surgical System · Dayvigo · ELIQUIS · Esbriet · FARXIGA · FASENRA · Flexitouch Plus · GENERAL PULMONARY · GLASSIA · Hillrom - Vest System Model 105 Home Care · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · ION · InogenOne · LONHALA MAGNAIR · LUMRYZ · Letairis · LifeVest · Monarch Platform · NUCALA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · ORENITRAM · PURIFIED CORTROPHIN GEL · Perforomist · Prolastin-C Liquid · Pulmonx Endobronchial Valve EBV · REMODULIN · Respiratoriy Care Undiv · SEEBRI NEOHALER · SILENOR · SMARTVEST · SPIRIVA · SPIRIVA RESPIMAT · STIOLTO · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · Spin · Sunosi · TAGRISSO · TEZSPIRE · TRELEGY ELLIPTA · TROKENDI XR · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · ULTRAFLEX · UPTRAVI · UTIBRON NEOHALER · Utibron · Vibativ · WAKIX · Wakix · Wellcentive Undiv · XARELTO · XOLAIR · XYREM · XYWAV · Xofluza · Xolair · Xyrem · YUPELRI · Yupelri · Zemaira · remede System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (89%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in critical care medicine and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for critical care medicine in TX.

Equivalent to $585 per 100 Medicare services performed
Looking for a critical care medicine in Denison?
Compare critical care medicines in the Denison area by procedure volume, costs, and industry payment transparency.
Browse critical care medicines nearby

Geographic Context

Critical Care Medicines within 10 mi
3
Per 100K population
2.1
County median income
$70,455
Nearest hospital
TEXOMA MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Kable is a mixed practice specialist, with above-average Medicare volume (top 0% in TX), and high industry engagement (speaking/promotional, top 1%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Kable experienced with omalizumab injection (xolair) for asthma/allergy?
Based on Medicare claims data, Dr. Kable performed 17,117 omalizumab injection (xolair) for asthma/allergy services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kable receive payments from pharmaceutical companies?
Yes. Dr. Kable received a total of $239,350 from 58 companies across 1,728 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kable's costs compare to other critical care medicines in Denison?
Dr. Kable's average Medicare payment per service is $35. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kable) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →